BRPI0517305A - formulação liofilizada estabilizada para derivados de cefalosporina - Google Patents
formulação liofilizada estabilizada para derivados de cefalosporinaInfo
- Publication number
- BRPI0517305A BRPI0517305A BRPI0517305-1A BRPI0517305A BRPI0517305A BR PI0517305 A BRPI0517305 A BR PI0517305A BR PI0517305 A BRPI0517305 A BR PI0517305A BR PI0517305 A BRPI0517305 A BR PI0517305A
- Authority
- BR
- Brazil
- Prior art keywords
- lyophilized formulation
- cephalosporin derivatives
- stabilized lyophilized
- derivatives
- formulation
- Prior art date
Links
- 229930186147 Cephalosporin Natural products 0.000 title abstract 3
- 229940124587 cephalosporin Drugs 0.000 title abstract 3
- 150000001780 cephalosporins Chemical class 0.000 title abstract 3
- 239000012931 lyophilized formulation Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
FORMULAçãO LIOFILIZADA ESTABILIZADA PARA DERIVADOS DE CEFALOSPORINA. A presente invenção refere-se a uma formulação liofihizada para derivados de cefalosporina com maior estabilidade, a uma solução para sua obtenção e a um método para a preparação dessa formulação, assim como ao uso de certos compostos para a estabilização de derivados de cefalosporina em formulações liofilizadas. Os compostos preferencialmente usados como estabilizadores de acordo com a invenção são o manitol, trealose e PVP.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04405690A EP1656930A1 (en) | 2004-11-10 | 2004-11-10 | Stabilized freeze-dried formulation for cephalosporin derivatives |
| PCT/CH2005/000665 WO2006050631A1 (en) | 2004-11-10 | 2005-11-10 | Stabilized freeze-dried formulation for cephalosporin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0517305A true BRPI0517305A (pt) | 2008-10-07 |
Family
ID=34932353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0517305-1A BRPI0517305A (pt) | 2004-11-10 | 2005-11-10 | formulação liofilizada estabilizada para derivados de cefalosporina |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20080032962A1 (pt) |
| EP (3) | EP1656930A1 (pt) |
| JP (1) | JP2008519775A (pt) |
| KR (1) | KR20070084150A (pt) |
| CN (1) | CN101056623B (pt) |
| AR (1) | AR052233A1 (pt) |
| AT (1) | ATE468844T1 (pt) |
| AU (1) | AU2005304252B2 (pt) |
| BR (1) | BRPI0517305A (pt) |
| CA (1) | CA2585296A1 (pt) |
| CY (1) | CY1110731T1 (pt) |
| DE (1) | DE602005021530D1 (pt) |
| DK (1) | DK1809253T3 (pt) |
| ES (1) | ES2342833T3 (pt) |
| HR (1) | HRP20100364T1 (pt) |
| MX (1) | MX2007005677A (pt) |
| MY (1) | MY142648A (pt) |
| PL (1) | PL1809253T3 (pt) |
| PT (1) | PT1809253E (pt) |
| RS (1) | RS51380B (pt) |
| SI (1) | SI1809253T1 (pt) |
| TW (1) | TW200630118A (pt) |
| WO (1) | WO2006050631A1 (pt) |
| ZA (1) | ZA200703760B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080103121A1 (en) * | 2006-10-30 | 2008-05-01 | Gole Dilip J | Cephalosporin derivative formulation |
| TWI482641B (zh) | 2006-12-07 | 2015-05-01 | Daiichi Sankyo Co Ltd | 含有低取代度羥丙基纖維素之醫藥組成物 |
| CN101600431B (zh) * | 2006-12-07 | 2011-09-07 | 第一三共株式会社 | 具有改进贮存稳定性的药物组合物 |
| JP2011514902A (ja) * | 2008-03-04 | 2011-05-12 | エラン・ファルマ・インターナショナル・リミテッド | 抗感染剤の安定な液体配合物および調節した抗感染剤投与計画 |
| EP2106788A1 (en) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Liquid and freeze dried formulations |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US20130089638A1 (en) | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
| CN102727451B (zh) * | 2012-07-03 | 2013-07-03 | 哈药集团制药总厂 | 一种含有头孢美唑钠的药物组合物 |
| CN102716075B (zh) * | 2012-07-03 | 2013-08-21 | 哈药集团制药总厂 | 一种含有头孢唑肟钠的药物组合物 |
| CN103271877A (zh) * | 2012-12-18 | 2013-09-04 | 张宏民 | 一种头孢西丁钠注射剂及其制备方法 |
| PT2968446T (pt) | 2013-03-13 | 2017-07-27 | Theravance Biopharma Antibiotics Ip Llc | Sais cloridrato de um composto antibiótico |
| CN110507619B (zh) * | 2019-08-19 | 2021-12-03 | 湖北美林药业有限公司 | 注射用头孢哌酮钠及其制备方法 |
| WO2022202994A1 (ja) * | 2021-03-25 | 2022-09-29 | ハウス食品グループ本社株式会社 | 乾燥ｐｒｅｎｃｓｏ組成物 |
| EP4316509A4 (en) * | 2021-03-25 | 2025-11-26 | House Foods Group Inc | TEAR FACTOR GENERATION KIT |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2690009B2 (ja) * | 1986-07-10 | 1997-12-10 | エーザイ 株式会社 | セフアロスポリン注射剤 |
| DE3801179A1 (de) * | 1988-01-18 | 1989-07-27 | Hoechst Ag | Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten |
| JP3129428B2 (ja) * | 1989-09-30 | 2001-01-29 | エーザイ株式会社 | セファロスポリン系薬物を含有する注射用組成物 |
| JPH0459730A (ja) * | 1990-06-26 | 1992-02-26 | Dai Ichi Seiyaku Co Ltd | セフェム系抗生物質含有凍結乾燥製剤 |
| BRPI9911178B8 (pt) * | 1998-06-15 | 2017-03-07 | Basilea Pharmaceutica Ag | derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenometil)-cefems, bem como preparação farmacêutica e uso dos mesmos |
| US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
| AU2003241675A1 (en) * | 2002-06-21 | 2004-01-06 | Shionogi And Co., Ltd. | Medicinal cephem compound composition for injection |
-
2004
- 2004-11-10 EP EP04405690A patent/EP1656930A1/en not_active Withdrawn
-
2005
- 2005-11-09 TW TW094139525A patent/TW200630118A/zh unknown
- 2005-11-09 AR ARP050104706A patent/AR052233A1/es not_active Application Discontinuation
- 2005-11-10 US US11/667,535 patent/US20080032962A1/en not_active Abandoned
- 2005-11-10 RS RSP-2010/0324A patent/RS51380B/sr unknown
- 2005-11-10 PL PL05798682T patent/PL1809253T3/pl unknown
- 2005-11-10 EP EP10162297A patent/EP2210592A3/en not_active Withdrawn
- 2005-11-10 HR HR20100364T patent/HRP20100364T1/hr unknown
- 2005-11-10 CA CA002585296A patent/CA2585296A1/en not_active Abandoned
- 2005-11-10 AT AT05798682T patent/ATE468844T1/de active
- 2005-11-10 WO PCT/CH2005/000665 patent/WO2006050631A1/en not_active Ceased
- 2005-11-10 MY MYPI20055270A patent/MY142648A/en unknown
- 2005-11-10 ES ES05798682T patent/ES2342833T3/es not_active Expired - Lifetime
- 2005-11-10 SI SI200531069T patent/SI1809253T1/sl unknown
- 2005-11-10 DK DK05798682.0T patent/DK1809253T3/da active
- 2005-11-10 CN CN2005800384621A patent/CN101056623B/zh not_active Expired - Fee Related
- 2005-11-10 BR BRPI0517305-1A patent/BRPI0517305A/pt not_active IP Right Cessation
- 2005-11-10 KR KR1020077010624A patent/KR20070084150A/ko not_active Withdrawn
- 2005-11-10 EP EP05798682A patent/EP1809253B1/en not_active Expired - Lifetime
- 2005-11-10 JP JP2007540473A patent/JP2008519775A/ja active Pending
- 2005-11-10 PT PT05798682T patent/PT1809253E/pt unknown
- 2005-11-10 AU AU2005304252A patent/AU2005304252B2/en not_active Ceased
- 2005-11-10 MX MX2007005677A patent/MX2007005677A/es active IP Right Grant
- 2005-11-10 DE DE602005021530T patent/DE602005021530D1/de not_active Expired - Lifetime
-
2007
- 2007-05-09 ZA ZA200703760A patent/ZA200703760B/en unknown
-
2010
- 2010-02-03 US US12/699,329 patent/US20100160278A1/en not_active Abandoned
- 2010-08-04 CY CY20101100728T patent/CY1110731T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20100364T1 (hr) | 2010-07-31 |
| CN101056623A (zh) | 2007-10-17 |
| RS51380B (sr) | 2011-02-28 |
| PL1809253T3 (pl) | 2010-10-29 |
| SI1809253T1 (sl) | 2010-09-30 |
| MX2007005677A (es) | 2007-07-20 |
| AU2005304252A1 (en) | 2006-05-18 |
| AU2005304252B2 (en) | 2009-07-16 |
| ATE468844T1 (de) | 2010-06-15 |
| AR052233A1 (es) | 2007-03-07 |
| ES2342833T3 (es) | 2010-07-15 |
| CY1110731T1 (el) | 2015-06-10 |
| DE602005021530D1 (de) | 2010-07-08 |
| EP1809253B1 (en) | 2010-05-26 |
| US20100160278A1 (en) | 2010-06-24 |
| CA2585296A1 (en) | 2006-05-18 |
| DK1809253T3 (da) | 2010-07-12 |
| CN101056623B (zh) | 2011-04-06 |
| JP2008519775A (ja) | 2008-06-12 |
| EP1656930A1 (en) | 2006-05-17 |
| KR20070084150A (ko) | 2007-08-24 |
| EP2210592A2 (en) | 2010-07-28 |
| WO2006050631A1 (en) | 2006-05-18 |
| MY142648A (en) | 2010-12-15 |
| EP1809253A1 (en) | 2007-07-25 |
| US20080032962A1 (en) | 2008-02-07 |
| PT1809253E (pt) | 2010-09-03 |
| ZA200703760B (en) | 2008-06-25 |
| EP2210592A3 (en) | 2011-12-14 |
| TW200630118A (en) | 2006-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0517305A (pt) | formulação liofilizada estabilizada para derivados de cefalosporina | |
| UY31209A1 (es) | Uso de homo y copolimeros para la estabilización de formulaciones de principios activos | |
| EP4360652A3 (en) | Adeno-associated virus formulations | |
| NZ596367A (en) | Lyophilized therapeutic peptibody formulations | |
| BRPI0511441B8 (pt) | composições contendo uma partícula de glucano oca ou partícula de parede celular encapsulando um componente de terpeno, métodos de fabricação e uso das mesmas | |
| EP3928800A3 (en) | Dry powder composition comprising long-chain rna | |
| EA200800781A1 (ru) | АМИДНЫЕ И КАРБАМАТНЫЕ ПРОИЗВОДНЫЕ АЛКИЛЗАМЕЩЕННЫХ N-[4-(4-АМИНО-1Н-ИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)БУТИЛ]МЕТАНСУЛЬФОНАМИДОВ И СПОСОБЫ | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| WO2010056991A8 (en) | Vaccine formulations and uses thereof | |
| CL2009000200A1 (es) | Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune. | |
| CY1114148T1 (el) | Γεφυρωμενες δικυκλικες αρυλο- και γεφυρωμενες δικυκλικες etepoapyλo-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις toy axl | |
| BR112018072264A2 (pt) | composição farmacêutica | |
| BRPI0615265A8 (pt) | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos | |
| NO20072714L (no) | Forbedret baereformulering | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| MX387269B (es) | Formulaciones de factor ix liofilizadas. | |
| EA200901365A1 (ru) | Стабилизированная фармацевтическая композиция, содержащая прегабалин | |
| AR046690A1 (es) | Composiciones de adn estabilizado para recubrir microproyecciones | |
| PE20141265A1 (es) | Formulaciones liofilizadas de fgf-18 | |
| BRPI0519312A2 (pt) | composiÇço biologicamente ativa, composiÇço de liofilizaÇço, mÉtodo para a liofilizaÇço de virossomas utilizando as composiÇÕes, liofilizado de virossoma, mÉtodo para reconstituiÇço de um liofilizado de virossoma, uso de qualquer uma das composiÇÕes, kit, e, uso de um derivado de colesterila catiânico | |
| WO2011069037A3 (en) | Stabilization and storage of biological pharmaceutical compositions | |
| WO2010079047A3 (en) | Octreotide depot formulation with constantly high exposure levels | |
| BRPI0519070A2 (pt) | composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa | |
| EA201991023A1 (ru) | Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |